Fostering collaborations and the career of a newly recruited pulmonary scientist

描述(由申请人提供)：国家犹太健康中心(NJH)的长期目标是通过直接的患者护理以及临床、转化和基础研究的协同组合来改善肺部疾病患者的生活。总体战略是招聘专注于肺部疾病和生物学的医生和科学家，并促进强有力的合作。具体地说，去年秋天，NJH在全国范围内寻找一位具有杰出研究背景并对呼吸道生物学和疾病感兴趣的内科科学家。由于这一努力，肺科成功地招募了一位杰出的、新独立的内科科学家加入教职员工，进行糖皮质激素信号的研究。Anthony Gerber博士于1998年在华盛顿大学获得医学博士/博士学位，并于2004年在加州大学旧金山分校完成培训。他最近开发了一项令人兴奋的研究计划，研究糖皮质激素信号的组织和启动子特定机制。这是一个与呼吸道生物学和NJH的目标密切相关的领域。糖皮质激素是临床医学中使用最广泛的药物之一，是治疗哮喘和其他免疫介导性疾病的核心药物。然而，严重的副作用和耐药性使其在临床上的使用变得复杂。糖皮质激素受体(GR)生物学和肺部治疗的一个关键问题是了解糖皮质激素信号的有益和有害影响，特别是肺内的细胞类型，并确定控制这些活动的分子机制。最先进的基因表达分析方法将被用来解决这一研究领域，这些方法广泛适用于肺部疾病的研究。有了PSO奖的资金，Gerber博士在糖皮质激素信号方面的研究计划将得到推进，在肺部疾病修改途径和基因表达的多路分析方面的合作将得到促进。这将通过以下方式实现：(1)对Gerber博士的实验室的基础设施进行投资，并雇用熟练的人员协助他的研究；(2)将多重基因表达分析的工具和方法整合到该部门/核心部门的其他研究人员的研究中；以及(3)成立一个委员会来监督Gerber博士的进展。 NJH在肺部和免疫介导性疾病的治疗和研究方面走在了前列，这些疾病困扰着数百万美国人。这个项目将促进对糖皮质激素信号的理解，糖皮质激素信号在许多疾病的治疗中是核心的。它还将促进一群专注于肺部疾病的杰出科学家之间的合作。

DESCRIPTION (provided by applicant): The long-term goal of National Jewish Health (NJH) is to improve the lives of patients with lung disease both through direct patient care, and a synergistic combination of clinical, translational and basic research. The general strategy is to recruit physicians and scientists that focus on lung disease and biology, and to foster strong collaborations. Specifically, last fall, NJH undertook a national search for a physician-scientist with an outstanding research background and an interest in airway biology and disease. As a result of this effort, the Pulmonary Division successfully recruited an outstanding, newly independent physician-scientist to join the faculty and conduct research on glucocorticoid signaling. Dr. Anthony Gerber received his MD/Ph.D. at the University of Washington in 1998, and completed his training at the University of California, San Francisco in 2004. He has recently developed an exciting research program on tissue and promoter specific mechanisms of glucocorticoid signaling. This is an area with significant relevance to airway biology and the goals of NJH. Glucocorticoids are among the most widely used drugs in clinical medicine and are central in the treatment of asthma and other immune-mediated diseases. However, severe side effects and resistance complicate their use in clinical practice. A key issue in glucocorticoid receptor (GR) biology and pulmonary therapeutics is to understand the beneficial and harmful effects of glucocorticoid signaling, in particular cell types within the lung, and to define the molecular mechanisms that control these activities. State-of-the-art multiplexed methods to analyze gene expression will be used to address this research area, methods that are broadly applicable to the study of lung disease. With the funds from the PSO award Dr. Gerber's research programs on glucocorticoid signaling will be advanced, collaborations on disease modifying pathways in the lung and multiplexed analysis of gene expression will be facilitated. This will be accomplished by (1) investments in infrastructure for Dr. Gerber's lab and employing skilled personnel to assist with his investigations, (2) integrating tools and methods for multiplexed gene expression analysis into the investigations of other researchers in the division/core, and (3) forming a committee to oversee Dr. Gerber's progress. NJH is at the forefront of the treatment and research of lung and immune-mediated diseases, which afflict millions of Americans. This project will advance the understanding of glucocorticoid signaling, which is central in the treatment of many diseases. It will also foster collaborations among a group of outstanding scientists focused on lung disease.